Data presented at New York Academy of Sciences LOS ANGELES, Calif., June 12, 2013 — Ritter Pharmaceuticals announced that data from its Phase 2 clinical study of RP-G28, in patients with lactose intolerance demonstrated the agent’s ability to alter the composition of microbes in patient’s intestines. The work was presented at the New York Academy […]